HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | A064065 | BAUSCH AND LOMB INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Lachman Consulting Services, Inc FDA-2020-P-2004 · 3 docket documents Lachman Consulting Services, Inc. filed this citizen petition requesting that the FDA designate Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension/Drops approved under ANDA 064065 as a new Reference Standard in the Orange Book, because the current Reference Standard and Reference L | 505(q) | 2020-10-06 | Withdrawn | Lachman Consulting Services, Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$3.83
per ml
Lowest NADAC/Unit
$3.83
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 24208063562NEOMYCIN-POLYMYXIN-HC EAR SUSP | $3.83 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.